Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis.

Competing Interests: Dr Harris has the following conflicts of interest: 3rd Rock Venture – Consultant (Fees); AbbVie, Inc – Consultant (Fees); Aclaris Therapeutics, Inc – Consultant (Fees), Investigator (Grants/Research Funding); Admirx – Consultant (Fees); Aldena – Consultant (Fees), Founder (Stock); Almiral – Consultant (Fees); AnaptysBio – Consultant (Fees); Avita – Consultant (Fees); BiologicsMD – Consultant (Fees); Boston Pharma – Consultant (Fees); BridgeBio – Consultant (Fees); Celgene – Investigator (Grants/Research Funding); Cogen Therapeutics – Consultant (Fees); Dermavant – Consultant (Fees), Investigator (Grants/Research Funding); Dermira – Consultant (Fees); EMD Serono – Consultant (Fees), Investigator (Grants/Research Funding); Frazier Management – Consultant (Fees); Genzyme/Sanofi – Consultant (Fees), Investigator (Grants/Research Funding); Granular Therapeutics, Inc – Consultant (Fees); Incyte – Consulting (Fees), Investigator (Grants/Research Funding), Equity; Janssen – Consultant (Fees); LEO Pharma – Consultant (Fees), Investigator (Grants/Research Funding); Matchpoint Therapeutics – Consultant (Fees); Merck – Consultant (Fees); NIRA Biosciences – Consultant (Fees), Founder (Stock); Pandion – Consultant (Fees); Pfizer – Consultant (Fees), Investigator (Grants/Research Funding); Platelet Biogenesis – Consultant (Fees); Rheos Medicines – Consultant (Fees), Investigator (Grants/Research Funding), Equity (Stock); Sonoma Biotherapeutics – Consultant (Fees); Steifel/GSK – Investigator (Grants/Research Funding); Sun Pharmaceuticals – Consultant (Fees), Investigator (Grants/Research Funding); Temprian Therapeutics – Consultant (Fees); TeVido BioDevices – Consultant (Fees), Investigator (Grants/Research Funding), Equity (Stock); Twi Biotech – Consultant (Fees); Villaris Therapeutics – Consulting (Fees), Investigator (Grants/Research Funding), Founder (Stock); Vimela Therapeutics – Consultant (Fees), Founder (Stock); Villaris Therapeutics was recently acquired by Incyte. All other authors have no conflicts of interest to disclose.